ProteoNic
Guido J. Kwikkers has extensive experience in financial leadership and management across various industries. Currently serving as CFO (a.i.) at ProteoNic since March 2010, Guido oversees financial operations for a company specializing in expression optimization technology for protein production. Prior to this role, Guido was the Managing Director and Finance Manager at CR Deutschland from October 2006 to May 2010, where responsibilities included financial oversight for a leading producer of aerosol spray cans in Europe and the U.S. Earlier, Guido was the Owner of GANDR from November 2003 to February 2007, focusing on made-to-measure clothing and corporate fashion. Guido holds a degree from Hanze University Groningen, obtained from 1998 to 2002.
This person is not in any teams
This person is not in any offices
ProteoNic
ProteoNic is a biotechnology company active in development and licensing of DNA technology for cell line generation and recombinant protein production for pharmaceutical applications. We offer premium vector technology that substantially boosts production levels of therapeutic proteins and other biologics. Cost savings are immediate and sizeable, freeing up production capacity and enabling commercially viable production of difficult to express proteins. ProteoNic’s 2G UNic™ drives higher production for all types of therapeutic protein products, including monoclonal antibodies, biosimilars and more difficult-to-express (DTE) proteins, such as Fc-fusion proteins and bi-specifics, contributing to their economic viability. Our patented technology does not require modifications to existing production systems or work flows and is compatible with all production cell lines and expression systems used in the industry. Independent technical and commercial validation by third parties, including top tier biopharma, demonstrates severalfold productivity level increases that translate into multi-million Euros in annual cost savings. The technology has wide ranging potential to boost production efficiencies in other important applications, including viral vector production, protein production in yeast and technologies which impact product quality. The company is headquartered at the BioScience Park in Leiden, the Netherlands and has a Boston, USA office for Business Development in the North American market.